Compare LAW & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAW | CABA |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.7M | 319.6M |
| IPO Year | 2021 | 2019 |
| Metric | LAW | CABA |
|---|---|---|
| Price | $4.34 | $3.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $8.00 | ★ $14.50 |
| AVG Volume (30 Days) | 175.6K | ★ 1.9M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.58 | 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $156,849,000.00 | N/A |
| Revenue This Year | $11.23 | N/A |
| Revenue Next Year | $10.60 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.29 | N/A |
| 52 Week Low | $2.45 | $1.11 |
| 52 Week High | $9.11 | $3.78 |
| Indicator | LAW | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 58.85 | 51.47 |
| Support Level | $3.91 | $2.11 |
| Resistance Level | $4.69 | $3.34 |
| Average True Range (ATR) | 0.22 | 0.22 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 92.89 | 55.30 |
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.